GlassScriptPhysician profile
Surjit B Singh
NPI 1578570172
$1,554.82
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $661 · 2021: $135 · 2022: $178 · 2023: $92.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $92.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $92.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $366.55 | 2019-2022 | |
| Allergan, INC. | $234.61 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $184.10 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $152.53 | 2020-2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $86.43 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.06 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $67.10 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $61.73 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.23 | 2020-2023 | |
| Abbvie INC. | $50.05 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $47.49 | 2019-2020 | |
| Indivior INC. | $44.47 | 2019 | |
| Eisai INC. | $39.83 | 2020-2022 | |
| Orexo US, INC. | $25.83 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.47 | 2023 | Austedo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.24 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surjit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.